Natco Pharma raises stake in Adcock Ingram to 49% after acquiring additional 13.25%

What Natco Pharma announced

On 14 July 2026, Natco Pharma Limited (NSE: NATCOPHARM, BSE: 524816) disclosed that it had completed the acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited, a leading South African pharmaceutical and healthcare company. The purchase raises Natco’s total shareholding in Adcock Ingram from 35.75% to 49%, just shy of a controlling interest. The transaction was carried out through Natco’s wholly‑owned subsidiary, Natco Pharma South Africa Proprietary Limited, and was completed after satisfaction of customary closing conditions and regulatory approvals.

Details of the acquisition

• Stake acquired: 13.25% of Adcock Ingram’s issued share capital, increasing Natco’s holding to 49%.
• Consideration: Approximately ZAR 1.81 billion, which the company translated to roughly ₹1,060 crore using the exchange rate prevailing at the time of closing.
• Transaction vehicle: Natco Pharma South Africa Proprietary Limited, a 100% owned subsidiary that handles Natco’s African operations.
• Background: Natco initially entered Adcock Ingram in 2025, acquiring a 35.75% stake as part of the South African firm’s delisting process. Shareholder approval was obtained in October 2025 and the first tranche closed in November 2025. The board subsequently approved the additional 13.25% acquisition in July 2026, and the deal was finalized later that month.
• Regulatory filing: The acquisition was announced through a Regulation 30 (LODR) press release filed with BSE and NSE on 14 July 2026.

About Adcock Ingram Holdings Proprietary Limited

Adcock Ingram, founded in 1891, is the second‑largest pharmaceutical player in South Africa, commanding a 10% share of the private market and leading the over‑the‑counter (OTC) segment. The company operates three manufacturing facilities in South Africa and two in India, producing a broad portfolio that includes prescription medicines, OTC products, consumer health items, and hospital‑grade pharmaceuticals. Well‑known brands such as Panado, Allergex, Epi‑max, Citro‑Soda, and Myprodol are part of its lineup. Adcock Ingram also supplies a significant portion of hospital and critical‑care products in the country.

Key facts at a glance

Why this matters for investors

The transaction is a strategic step in Natco’s long‑term African growth plan. By moving its holding to 49%, Natco gains near‑majority influence over Adcock Ingram’s board and strategic decisions, without triggering the mandatory offer thresholds that would apply at 50% or higher. The deal does not involve issuance of new Natco shares, so there is no immediate dilution for existing shareholders. However, the sizeable cash outlay of roughly ₹1,060 crore will be reflected in Natco’s balance sheet and may affect short‑term liquidity ratios. The acquisition also diversifies Natc​o’s revenue base, adding exposure to the South African market, which is a high‑growth region for pharmaceuticals, especially in OTC and hospital segments.

From a regulatory perspective, the filing satisfies SEBI’s Listing Obligations and Disclosure Requirements, ensuring transparency for market participants. The transaction was completed after meeting all customary closing conditions, indicating that no further approvals are pending for the acquisition itself.

Conclusion

Natco Pharma has successfully increased its stake in Adcock Ingram to 49% by paying roughly ₹1,060 crore for an additional 13.25% equity. The acquisition, executed through its South African subsidiary, aligns with Natco’s strategy to deepen its footprint in Africa and gain greater operational influence over a market‑leading pharmaceutical company. While the deal is cash‑intensive, it does not dilute existing shareholders and positions Natco for potential upside from Adcock Ingram’s strong market position. All regulatory filings have been completed, and the transaction is now part of Natco’s consolidated financial statements.